Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019 | ||||||||||||||||||||||||||||||||||||
| By: Nasdaq / GlobeNewswire - 23 Jul 2019 | Back to overview list |
|||||||||||||||||||||||||||||||||||
SAN DIEGO and TORONTO, July 23, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, will release its financial results for the second quarter ended June 30, 2019 on Tuesday, August 6, 2019 after the close of the market. Conference Call & Webcast:
Replays available through August 20, 2019
The live conference call can also be accessed through a link on the Investor Relations section of Aptose’s website at ir.aptose.com. Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast along with a transcript will be available on the company’s website for 30 days. The press release, the financial statements and the management’s discussion and analysis for the quarter ended June 30, 2019 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml. About Aptose Biosciences Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS. CG-806, an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor being developed to treat AML and certain B cell malignancies, is in a Phase 1 clinical trial for hematologic malignancies. For further information, please visit www.aptose.com. For further information, please contact:
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
 | Back to overview list | |||||||||||||||||||||||||||||||||||